The overall output of the Japanese drug industry measured by expected peak sales potential of newly National Health Insurance (NHI)-reimbursed drugs surged to $34 billion between 2010-2014, up from $16.9 billion during 2005-2009, according to Evaluate’s new report, 

		Peak sales forecast of newly reimbursed drugs surged to $34 billion between 2010-14 compared to $16.9 billion during 2005-09.

		Quantity of reimbursed drugs increased 8 percent to 64 in 2014 vs. 2013; peak sales forecasts increased 19 percent in 2014 to $6.3 billion.

		The median reimbursed price for Japanese drugs between 2005-14 was 40 percent lower than the US; 20 percent lower than Germany.

		New endocrine drugs have the highest peak sales potential with central nervous system drugs coming in second.

		Median annual cost of new drugs jumped to $837 (¥95k) in 2010-14 from $697 (¥82k) in 2005-09.

	The full version of the report can be downloaded at 

www.evaluategroup.com/JapanSalesVolumePricing2015